ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
68,118.51
0.58%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
02/06/202415:00PR Newswire (US)MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer
02/06/202415:00PR Newswire (US)Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC)
02/06/202414:47PR Newswire (US)Federal Government Authorizes Institute of Information Management to Certify Data Protection Professionals in Nigeria
02/06/202414:43PR Newswire (US)Federal Government Authorizes Institute of Information Management to Certify Data Protection Professionals in Nigeria
02/06/202414:30PR Newswire (US)Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care
02/06/202413:42PR Newswire (US)Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
02/06/202413:30PR Newswire (US)Vention to democratize industrial automation using NVIDIA AI technologies
02/06/202413:30PR Newswire (US)Crimson Cup Coffee & Tea Publishes 2024 Guide on How to Start a Coffee Shop in California
02/06/202413:00PR Newswire (US)OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
02/06/202412:00PR Newswire (US)Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service
02/06/202411:41Alliance NewsAlliance NewsIsrael fights Hamas as mediators urge both to accept Gaza truce plan
02/06/202411:35Alliance NewsAlliance NewsOPEC+ anxious to maintain unity as some members head to Riyadh
02/06/202411:32Alliance NewsAlliance NewsDong Jun says Beijing ready to "forcefully" stop Taiwan independence
02/06/202411:29Alliance NewsAlliance NewsNvidia head, top chip CEOs to lay out AI plans at Taiwan expoTG:NVDNVIDIA Corp
02/06/202411:20Alliance NewsAlliance NewsPRESS: Sanofi proceeds with EUR20 billion consumer healthcare spin-off
02/06/202411:18PR Newswire (US)Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
02/06/202404:56PR Newswire (US)Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
02/06/202401:25PR Newswire (US)Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
02/06/202401:17PR Newswire (US)CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
02/06/202400:13PR Newswire (US)GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO A
01/06/202423:09PR Newswire (US)LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
01/06/202423:06PR Newswire (US)NAISMA Announces PlayCleanGo® Awareness Week 2024: Real People, Real Stories
01/06/202422:52PR Newswire (US)Sun Bum Makes SPF Waves in Miami with its Largest Ever Beach Hangout for Skin Cancer Awareness Month
01/06/202421:30PR Newswire (US)Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
01/06/202420:40PR Newswire (US)BIOHACKING CONFERENCE ANNOUNCES STEMREGENⓇ WILL RETURN AS TITLE SPONSOR FOR 2025
01/06/202420:00PR Newswire (US)Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
01/06/202419:08PR Newswire (US)Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
01/06/202418:55PR Newswire (US)Back Nine Greens Announce a New Dealer: North Texas Luxury Lawns
01/06/202418:45PR Newswire (US)Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesNASDAQ:KPTIKaryopharm Therapeutics Inc
01/06/202418:42PR Newswire (US)Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US

Your Recent History

AMEX
RFA
Black Rock FL Invest
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved